| Name | Title | Contact Details |
|---|
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
Compliance Associates is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina`s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible. At SkylineDx we transform life sciences into the daily practice of clinical diagnostics. We enable patients to benefit sooner and safer from new insights in the molecular basis of disease. We can truly make a difference by making our love of life tangible as state-of-the-art diagnostic products with a high clinical value. Our products are designed to support clinicians in making the right choices for their patients. This provides a unique and very real difference. Obvious perhaps, but never taken for granted here at SkylineDx.
CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIPs development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.